What is Buffett's favorite stock?
Warren Buffett is most famous for his long-term investment in Coca-Cola, a stock that he has held in his portfolio for decades and often describes as one of his quintessential investments. He favors Coca-Cola not just for its brand power, but for its "moat"—a term he uses to describe a company's sustainable competitive advantage, such as its massive global distribution network, high brand loyalty, and recurring cash flow. For Buffett, Coca-Cola is the perfect example of a "wonderful business" that he can buy at a "fair price." While he holds various stocks in the Berkshire Hathaway portfolio, his public affection and deep, multi-decade commitment to Coca-Cola serve as a masterclass in his investment style: patience, focus on fundamental value, and the recognition of businesses with simple models that will remain relevant for generations. It is a reflection of his conviction that a truly great company will continue to compound its earnings over time, regardless of short-term market noise.
Related FAQs
McKesson possesses characteristics typical of an exceptional long-term investment, underpinned by its irreplaceable infrastructure in pharmaceutical supply chains and expanding margins in high-growth oncology and specialty care segments.
McKesson Corporation is a massive American healthcare services and pharmaceutical distribution enterprise headquartered in Irving, Texas, operating as one of the largest healthcare supply chain companies in the world.
McKesson has not released any corporate announcements or filings indicating plans for a stock split.
On July 22, 2026, the Board of Directors of McKesson Corporation (NYSE: MCK) declared a regular quarterly dividend of $0.94 per share of common stock. This represents a 15% increase from the previous quarterly dividend of $0.82 per share.
Yes, Costco Wholesale Corporation uses the OneStream Intelligent Finance platform.
Warren Buffett does not hold shares of MercadoLibre, as the Latin American e-commerce and digital payments titan falls outside his core circle of competence and value-investing framework.
Institutional equity research analysts tracking McKesson Corporation (NYSE: MCK) project a strong valuation outlook for 2026, with consensus 12-month price targets averaging around $926 to $939.
McKesson has not announced any upcoming stock split configurations through official regulatory filings or executive communications distributed to shareholders.
Equity research analysts evaluate McKesson Corporation (MCK) with robust and positive long-term growth prospects, supported by its dominant market position as one of the largest pharmaceutical distribution and healthcare services enterprises in North...
Executive compensation for the chief executive officer guiding MDU Resources Group, Inc. (a diversified natural resource, regulated energy delivery, and construction materials enterprise) reflects corporate governance benchmarks.
Evaluating whether McKesson stock is undervalued involves analyzing its historical price-to-earnings ratios, free cash flow generation, and double-digit earnings growth against its peers in the healthcare distribution sector.
Executive leadership compensation at Medline Industries—a massive privately held manufacturer and distributor of medical supplies—operates largely through private corporate governance structures rather than public SEC proxy disclosures.
Determining whether Medline or McKesson is better depends largely on the specific operational scope and needs of the healthcare facility utilizing their services.
McKesson is widely regarded by institutional portfolio managers as a high-quality equity investment, supported by defensive business characteristics, reliable cash flows, and strong secular tailwinds in pharmaceutical demand.
McKesson does not face widespread or systemic corporate layoffs, though like any large multinational enterprise, it routinely manages localized workforce realignments, operational efficiencies, and structural adjustments following portfolio divestitu...
McKesson Corporation is definitively an American enterprise, maintaining its corporate headquarters in Irving, Texas, and tracing its historical roots back to the nineteenth century in New York.
McKesson Corporation does not operate as a traditional pharmacy benefit manager (PBM) that negotiates drug formularies and rebates on behalf of insurance health plans in the manner typical of standalone PBM giants.
Wall Street equity analysts tracking McKesson Corporation (MCK) generally highlight its dominant role as a premier healthcare distributor and pharmaceutical services provider, supporting favorable buy ratings underpinned by steady revenue growth and ...